Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/23471
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2021-12-22T13:44:34Z | - |
dc.date.available | 2021-12-22T13:44:34Z | - |
dc.date.issued | 1999-11-15 | - |
dc.identifier.citation | Özçelik, T. vd. (1999). "Evaluating acute cardiotoxicity of Idarubicin in acute leukemia patients". Blood, 94(10), Supplement 1, Part 2, 235B-235B. | en_US |
dc.identifier.issn | 0006-4971 | - |
dc.identifier.uri | http://hdl.handle.net/11452/23471 | - |
dc.language.iso | en | en_US |
dc.publisher | Amer Soc Hematology | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Hematology | en_US |
dc.title | Evaluating acute cardiotoxicity of Idarubicin in acute leukemia patients | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000083790701101 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı. | tr_TR |
dc.identifier.startpage | 235B | tr_TR |
dc.identifier.endpage | 235B | tr_TR |
dc.identifier.volume | 94 | tr_TR |
dc.identifier.issue | 10, Supplement 1, Part 2 | en_US |
dc.relation.journal | Blood | en_US |
dc.contributor.buuauthor | Özçelik, Tülay | - |
dc.contributor.buuauthor | Ali, Rıdvan | - |
dc.contributor.buuauthor | Serdar, Akın | - |
dc.contributor.buuauthor | Özkalemkaş, Fahir | - |
dc.contributor.buuauthor | Tunalı, Ahmet | - |
dc.contributor.buuauthor | Özkocaman, Vildan | - |
dc.contributor.buuauthor | Kaya, Kubilay | - |
dc.contributor.researcherid | AAG-8495-2021 | tr_TR |
dc.contributor.researcherid | AAH-1854-2021 | tr_TR |
dc.subject.wos | Hematology | en_US |
dc.wos.quartile | Q1 | en_US |
Appears in Collections: | Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.